Akero Therapeutics is advancing new medicines designed to treat serious metabolic diseases by restoring metabolic balance. The company's lead compound is AKR-001, a novel long-acting FGF21 analogue. Akero plans to begin Phase 2 clinical studies of AKR-001 for the treatment of NASH.
Company Name
Akero Therapeutics (AKRO)Company Website
http://www.akerotx.com/Location
South San Francisco, Calif.Investment Stage
IPO June 2019Connected News
- Akero Therapeutics Announces Pricing of Initial Public Offering
- Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases
- Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer
- Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases